skip to main
|
skip to sidebar
KinasePro
Daily news on kinase inhibitors.
Showing posts with label
Src
.
Show all posts
Showing posts with label
Src
.
Show all posts
Sunday, August 31, 2008
Src - University of Rhode Island
Development of Src tyrosine kinase substrate binding site inhibitors.
Ye G, Tiwari R, Parang K.
Older Posts
Home
Subscribe to:
Posts (Atom)
Labels
550
(1)
Abbott
(1)
Akt
(1)
Amgen
(1)
Angiokinase
(1)
Astellas
(1)
Aurora2
(1)
Axitinib
(1)
B-Raf
(2)
BMS
(2)
Boehringer Ingelheim
(1)
C-MET
(2)
CAMK2A
(1)
CDK
(1)
CEP-1347
(1)
Cephalon
(2)
CK1e
(1)
Clinical Trial
(10)
Computational
(4)
CP-690
(1)
Dasatinib
(1)
Eberhard-Karls-University Tuebingen
(1)
EGFR
(1)
Genentech
(1)
GSK
(2)
GSK3
(1)
IGF-1R
(1)
IRAK4
(1)
JAK2
(1)
JNK
(1)
Lapatinib
(1)
Lck
(1)
Motesanib
(1)
mTOR
(1)
Nilotinib
(1)
p38
(2)
PDB
(3)
PDK1
(1)
Pfizer
(3)
Phase II
(1)
PI3K
(2)
Pim1
(1)
Piramed
(1)
PKA
(1)
PLK
(1)
Plk1
(1)
Riboxistaurin
(1)
Sorafenib
(1)
Src
(1)
Sunitinib
(1)
Tie1
(1)
TrkA
(1)
UCB
(1)
University of Florida
(1)
University of Kentucky
(1)
University of Pittsburgh
(1)
University of Rhode Island
(1)
Blog Archive
▼
2009
(1)
▼
07/05 - 07/12
(1)
CP-690,550 Phase II RA Results
►
2008
(32)
►
09/07 - 09/14
(3)
►
08/31 - 09/07
(10)
►
08/24 - 08/31
(11)
►
08/17 - 08/24
(8)
On the Market
Dasatinib
Erlotinib
Gefitinib
Imatinib
Lapatinib
Nilotinib
Temsirolimus
